Form 4: Orchestra BioMed Director Acquires Stock Options

Orchestra BioMed Holdings, Inc. director Aryeh Jason was granted stock options for 42,553 shares.

Summary

• Orchestra BioMed Holdings, Inc. director Aryeh Jason has been granted stock options.
• The grant includes options to purchase 42,553 shares of common stock.
• The exercise price for these options is $4.04 per share.
• These options are set to vest on the one-year anniversary of June 23rd, 2026, provided continuous service is maintained.
• The options have an expiration date of June 23rd, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a common compensation practice and does not inherently signal positive or negative company performance.

Positives

• Director Aryeh Jason has been granted stock options, indicating a potential alignment of management interests with shareholder value.
• The grant of 42,553 options provides a significant incentive for the director to contribute to the company's growth and stock price appreciation.
• The long expiration date of June 23rd, 2036, allows for a substantial period for the options to potentially become valuable.

Risks

• The value of the stock options is contingent on the future performance of Orchestra BioMed Holdings, Inc. and its stock price exceeding the $4.04 exercise price.
• Vesting is subject to the Reporting Person's continuous service, meaning any departure from the company before the vesting date would result in forfeiture of the options.

Future Outlook

The stock options granted to Aryeh Jason are exercisable at $4.04 and vest one year from the grant date of June 23rd, 2026, expiring on June 23rd, 2036. Their future value is dependent on the company's stock performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and healthcare sectors to incentivize long-term performance and align executive interests with those of shareholders.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns management's interests with increasing shareholder value, but the dilutive effect of future share issuance upon exercise should be considered.
• Employees: This filing does not directly impact employees, but it reflects a common compensation strategy that may be mirrored for other key personnel.
• Management: The options provide a financial incentive for the director to perform well and contribute to the company's success.

Next Steps

• The director must maintain continuous service through June 23rd, 2027, for the stock options to vest.
• The director may exercise the vested stock options anytime between June 23rd, 2027, and June 23rd, 2036.

Key Dates

Keywords

Orchestra BioMed Holdings, OBIO, Form 4, Stock Options, Insider Trading, Beneficial Ownership, Director Compensation, Securities Exchange Act